Pembrolizumab, Paclitaxel and Carboplatin for Advanced or Recurrent Endometrial Cancer

This study is exploring the effectiveness of a drug called Pembrolizumab (MK-3475) when combined with standard chemotherapy treatments, Paclitaxel and Carboplatin, for women with advanced or recurrent endometrial cancer. The primary goal is to see if adding Pembrolizumab to the standard treatment can improve outcomes for these patients. The study is particularly interested in understanding how this combination therapy works for different types of endometrial cancer, specifically those with mismatch repair protein proficient (pMMR) or mismatch repair deficiency (dMMR). This research is important as it could potentially lead to improved treatments and better quality of life for women with advanced or recurrent endometrial cancer. During the study, participants are randomly assigned to one of two groups. One group receives the standard chemotherapy treatments along with a placebo, while the other group receives the same chemotherapy treatments but with Pembrolizumab instead of the placebo. Both groups receive their treatments every three weeks for six cycles, with the possibility of extending to ten cycles if necessary. After the initial treatment phase, participants enter a maintenance phase where they continue to receive either the placebo or Pembrolizumab every six weeks for up to 14 cycles. Throughout the study, participants undergo regular CT scans to monitor their progress. The study measures the effectiveness of the treatments by looking at progression-free survival rates, the nature and frequency of side effects, and the impact on patients' physical function and quality of life.